救济治疗机构宣布,作为急性呼吸困难综合征药物候选体的RLF-OD032的生物当量结果呈阳性,这是朝着批准方向迈出的关键一步。 Relief Therapeutics announces positive bioequivalence results for RLF-OD032, a drug candidate for acute respiratory distress syndrome, a key step toward approval.

救济治疗报告表明,对候选药物RLF-OD032进行的关键生物等效研究取得了积极的成果,该药物有可能治疗急性呼吸困难综合症。 Relief Therapeutics reports positive results from a pivotal bioequivalence study of its drug candidate RLF-OD032, a potential treatment for acute respiratory distress syndrome. 该研究达到了其主要终点,显示了与参考产品的生物等同性,这是朝向管制批准和潜在的商业化迈出的关键一步。 The study met its primary endpoint, demonstrating bioequivalence to the reference product, a key step toward regulatory approval and potential commercialization. 该公司计划向监管当局提交数据以供审查。 The company plans to submit data to regulatory authorities for review.